Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb placebo-controlled study of intravenous cinaciguat in acute decompensated chronic congestive heart failure
2009-014378-16Phase 2Terminated
- Sponsor
- Bayer
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cinaciguat in chronic heart failure (CHF) and Acute Heart Failure (AHF) (3 arms), sponsored by Bayer. Primary endpoint: Change in pulmonary capillary wedge pressure from baseline to 8 hours. Started Nov 2009; status: terminated.
02
Drugs
cinaciguat
03
Conditions
chronic heart failure (CHF)Acute Heart Failure (AHF)
Beyond the preview
Go deeper on 2009-014378-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014378-16.